Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05101902 · ClinicalTrials.gov registry record
A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])
A clinical trial, sponsored by Adrenas Therapeutics.
- Completed
- Registry status
- 65
- Enrollment target
NCT05101902 is a clinical trial that has completed, run by Adrenas Therapeutics. The registered enrollment target is 65 participants.
The verdict
NCT05101902 has completed, sponsored by Adrenas Therapeutics.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 \[NCT04783181\] gene therapy trial with BBP-631.
Interventions
- OTHER Pre-Screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2024-08-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05101902
The ClinicalTrials.gov registry entry for NCT05101902 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adrenas Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pre-Screening is the first listed.
NCT05101902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05101902 about?
NCT05101902 is a clinical study titled "A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])". This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 \[NCT04783181\] gene therapy trial with BBP-631.
What is the current status of trial NCT05101902?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2021-07-01. Estimated completion is 2024-08-07.
What interventions are being tested in trial NCT05101902?
The interventions under investigation include: Pre-Screening (OTHER).
Who is sponsoring clinical trial NCT05101902?
This trial is sponsored by Adrenas Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.